1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine has been researched along with Behavior Disorders in 5 studies
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lu, C | 1 |
| Wei, Y | 1 |
| Hu, R | 1 |
| Wang, Y | 1 |
| Li, K | 1 |
| Li, X | 1 |
| Shan, S | 1 |
| Hong-Min, T | 1 |
| Yi, F | 1 |
| Jun-Peng, G | 1 |
| Yue, F | 1 |
| Yan-Hong, T | 1 |
| Yun-Ke, Y | 1 |
| Wen-Wei, L | 1 |
| Xiang-Yu, W | 1 |
| Jun, M | 1 |
| Guo-Hua, W | 1 |
| Ya-Ling, H | 1 |
| Hua-Wei, L | 1 |
| Ding-Fang, C | 1 |
| Sheline, CT | 1 |
| Zhu, J | 1 |
| Zhang, W | 1 |
| Shi, C | 1 |
| Cai, AL | 1 |
| Fox, SH | 1 |
| Visanji, NP | 1 |
| Johnston, TH | 1 |
| Gomez-Ramirez, J | 1 |
| Voon, V | 1 |
| Brotchie, JM | 1 |
| Zhu, XR | 1 |
| Maskri, L | 1 |
| Herold, C | 1 |
| Bader, V | 1 |
| Stichel, CC | 1 |
| Güntürkün, O | 1 |
| Lübbert, H | 1 |
5 other studies available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Behavior Disorders
| Article | Year |
|---|---|
Transcranial Direct Current Stimulation Ameliorates Behavioral Deficits and Reduces Oxidative Stress in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Dopamine; Glut | 2015 |
New evidences for fractalkine/CX3CL1 involved in substantia nigral microglial activation and behavioral changes in a rat model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antibodies; Antiparkins | 2011 |
Mitochondrial inhibitor models of Huntington's disease and Parkinson's disease induce zinc accumulation and are attenuated by inhibition of zinc neurotoxicity in vitro or in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carrier Proteins; Cation Transport Proteins; | 2013 |
Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Disease Models, Animal; Dopamine | 2006 |
Non-motor behavioural impairments in parkin-deficient mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Age Factors; Analysis of Variance; Animals; Animals, N | 2007 |